11:12 AM EDT, 04/05/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.27% to 1,369.92 on the S&P Europe Select ADR Index. However, the gain isn't enough to pull the index out of negative territory for the week.

From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies ( DBVT ) and biotech firm Evaxion Biotech ( EVAX ) , which rose 4.2% and 1.6%, respectively. They were followed by internet browser company Opera (OPRA) and pharmaceutical company Novo Nordisk ( NVO ) , which increased 1.3% each.

The decliners from continental Europe were led by semiconductor company Sequans Communications ( SQNS ) and biopharmaceutical company Genfit ( GNFT ) , which dropped 8.2% and 5%, respectively. They were followed by biopharmaceutical company Calliditas Therapeutics ( CALT ) and hotel booking site trivago (TRVG), which lost 2.9% and 1.8% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics ( AKTX ) and Adaptimmune Therapeutics ( ADAP ) , which rose 4.3% and 3%, respectively. They were followed by biopharmaceutical company Verona Pharma ( VRNA ) and biotech firm Trinity Biotech ( TRIB ) , which were up 2.2% and 2%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Amarin ( AMRN ) and utilities company National Grid ( NGG ) , which fell 3.3% and 3%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals ( BDRX ) and software firm Endava ( DAVA ) , which fell 2.6% and 1.4%, respectively.